How big is the Asthma Drugs Market?

The Asthma Drugs Market size is expected to reach USD 25.90 billion in 2024 and grow at a CAGR of 5.88% to reach USD 36.73 billion by 2029. Read More

What is the current Asthma Drugs Market size?

In 2024, the Asthma Drugs Market size is expected to reach USD 25.90 billion. Read More

Who are the key players in Asthma Drugs Market?

AstraZeneca, Boehringer Ingelheim GmbH, Novartis AG, Sanofi and Merck & Co. Inc. are the major companies operating in the Asthma Drugs Market. Read More

Which is the fastest growing region in Asthma Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Asthma Drugs Market?

In 2024, the North America accounts for the largest market share in Asthma Drugs Market. Read More

What years does this Asthma Drugs Market cover, and what was the market size in 2023?

In 2023, the Asthma Drugs Market size was estimated at USD 24.38 billion. The report covers the Asthma Drugs Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Asthma Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Asthma Drugs Market Size & Share Analysis - Industry Research Report

Asthma Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Asthma Drugs Market Report is Segmented by Drug Class (Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs) and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Report Offers the Values (USD) for all the Above Segments.

Asthma Drugs Industry Overview

The asthma drugs market is moderately fragmented. Due to the growth opportunities, many new players are emerging in the asthma drug market. Forthcoming patent expiries of major drugs are expected to increase competition, further driving the market, especially in the generic sector. The market is expected to grow significantly, with several generic players controlling significant market shares in the developing regions. Some of the market players include AstraZeneca PLC, Boehringer Ingelheim GmbH, Novartis AG, Sanofi SA, and Merck & Co. Inc.